Pharmacogenomics & Personalized Medicine SCIE

國(guó)際簡(jiǎn)稱：PHARMACOGEN PERS MED 參考譯名：藥物基因組學(xué)和個(gè)性化醫(yī)學(xué)

主要研究方向：Biochemistry, Genetics and Molecular Biology-Molecular Medicine 非預(yù)警期刊審稿周期： 16 Weeks

《藥物基因組學(xué)和個(gè)性化醫(yī)學(xué)》(Pharmacogenomics & Personalized Medicine)是一本由Dove Medical Press出版的以Biochemistry, Genetics and Molecular Biology-Molecular Medicine為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預(yù)警名單。

4區(qū) 中科院分區(qū)
Q3 JCR分區(qū)
93 年發(fā)文量
1.8 IF影響因子
開放是否OA
1 issue/year 出版周期
English 出版語言

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.

In particular, emphasis will be given to:

Genomic and proteomic profiling

Genetics and drug metabolism

Targeted drug identification and discovery

Optimizing drug selection & dosage based on patient's genetic profile

Drug related morbidity & mortality intervention

Advanced disease screening and targeted therapeutic intervention

Genetic based vaccine development

Patient satisfaction and preference

Health economic evaluations

Practical and organizational issues in the development and implementation of personalized medicine programs.

[ 查看全部 ]

投稿咨詢加急咨詢

Pharmacogenomics & Personalized Medicine期刊信息

ISSN：1178-7066
出版語言：English
是否OA：開放
E-ISSN：1178-7066
出版地區(qū)：New Zealand
是否預(yù)警：否
出版商：Dove Medical Press
出版周期：1 issue/year
開源占比：0.9833
Gold OA文章占比：98.46%
OA被引用占比：1
出版國(guó)人文章占比：0.23
出版撤稿占比：0
研究類文章占比：86.02%

Pharmacogenomics & Personalized Medicine CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

3.3

0.508

0.544

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q3	199 / 313	36%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Molecular Medicine	Q3	134 / 178	25%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。

Pharmacogenomics & Personalized Medicine中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	4區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	4區(qū)

中科院 2021年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

中科院 2021年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

中科院 2020年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū)

Pharmacogenomics & Personalized Medicine JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q3	240 / 354	32.3%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q3	215 / 354	39.41%

Pharmacogenomics & Personalized Medicine歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Pharmacogenomics & Personalized Medicine中國(guó)學(xué)者發(fā)文選摘

1、Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation
Author: Zhong, Lan; Yin, Rutie; Song, Liang

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 195-200. DOI: 10.2147/PGPM.S397827
2、Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma
Author: Zheng, Chunlan; Peng, Yanan; Wang, Haizhou; Wang, Youwei; Liu, Lan; Zhao, Qiu

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 39-58. DOI: 10.2147/PGPM.S397892
3、NOTCH2, ATIC, MRI1, SLC6A13, ATP13A2 Genetic Variations are Associated with Ventricular Septal Defect in the Chinese Tibetan Population Through Whole-Exome Sequencing
Author: Zhang, Xiaohui; Zhen, Da; Li, Xuemei; Yi, Faling; Zhang, Zhanhao; Yang, Wei; Li, Xuguang; Sheng, Yemeng; Liu, Xiaoli; Jin, Tianbo; He, Yongjun

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 389-400. DOI: 10.2147/PGPM.S404438
4、The Allelic Expression of RNA Editing Gene ADARB1 in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
Author: Zeng, Jiajia; Han, Linyu; Wang, Teng; Huang, Linying; Zheng, Yanxiu; Zhang, Nasha; Li, Ziqiang; Yang, Ming

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 229-238. DOI: 10.2147/PGPM.S402115
5、LncRNA FOXD2-AS1 Increased Proliferation and Invasion of Lung Adenocarcinoma via Cell-Cycle Regulation
Author: Yuan, Yuan; Yu, Peng; Shen, Huihua; Xing, Guozhu; Li, Wu

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 99-109. DOI: 10.2147/PGPM.S396866
6、Dysregulation of circRNA-0076906 and circRNA-0134944 is Correlated with Susceptibility to Osteoporosis and Osteoporotic Fracture in Postmenopausal Females from the Chinese Han Population
Author: Yang, Weijie; Zhang, Wei; Li, Fengqian; Xu, Ning; Sun, Ping

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 183-194. DOI: 10.2147/PGPM.S394757
7、Massive Hepatocellular Carcinoma with Situs Inversus Totalis Achieved a Complete Response Following Camrelizumab Plus Apatinib and Combined with Two-Stage Hepatectomy: A Case Report
Author: Wu, Yining; Ou, Shenjian; Liao, Xiwen; Han, Chuangye; Yang, Chengkun; Qin, Wei; Tan, Yufeng; Lao, Quan; Peng, Tao; Ye, Xinping

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 111-120. DOI: 10.2147/PGPM.S376596
8、Acute Myeloid Leukemia Secondary to Chronic Lymphocytic Leukemia After Prolonged Chlorambucil Therapy: A Case Report
Author: Wu, Yan; Liu, Shan; Wang, Dongmei; Yao, Xinjie

Journal: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2023; Vol. 16, Issue , pp. 401-405. DOI: 10.2147/PGPM.S407940